Warning: This website describes our product, which has not been approved or cleared for marketing by the U.S. Food and Drug Administration and is considered an investigational device.
about us
Pykus Therapeutics was founded in 2016 with the mission to improve the patient care experience following retinal surgery. As physicians, we have heard our patients describe the significant burdens that retina surgery places on them during recovery. We embarked to develop PYK-1107, a novel biodegradable polymer for retinal tamponade.
what is retina surgery?
More than 1.8 million retina surgeries, or vitrectomies, are performed every year to treat serious eye diseases. Often such surgeries require the insertion of gases or oils into the eye which impose a significant burden on patients during post-operative recovery.
What is PYK-1107?
PYK-1107 is Pykus Therapeutics’ lead product. It is a novel, in situ cross linking, biodegradable hydrogel. PYK-1107 is administered in the operating room and is designed to allow the retina to heal without requiring facedown positioning, blurred vision, prohibition on air travel, or a need for repeat surgery.